A Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719

NCT01362257 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Treatment Period 1 - IV dose of GSK573719
DRUG: Treatment Period 2 - Oral dose of GSK573719

Sponsor

GlaxoSmithKline